KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2016 - 2024)

Historic Asset Writedowns and Impairment for TherapeuticsMD (TXMD) over the last 13 years, with Q4 2024 value amounting to $7000.0.

  • TherapeuticsMD's Asset Writedowns and Impairment changed N/A to $7000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $7000.0, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A changed from last year.
  • TherapeuticsMD's Asset Writedowns and Impairment amounted to $7000.0 in Q4 2024.
  • In the past 5 years, TherapeuticsMD's Asset Writedowns and Impairment ranged from a high of $500000.0 in Q4 2020 and a low of -$122621.0 during Q1 2020
  • In the last 5 years, TherapeuticsMD's Asset Writedowns and Impairment had a median value of $115000.0 in 2020 and averaged $132833.3.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 24902.17% in 2020, then skyrocketed by 46208.09% in 2021.
  • Quarter analysis of 5 years shows TherapeuticsMD's Asset Writedowns and Impairment stood at $500000.0 in 2020, then plummeted by 101.4% to -$7000.0 in 2021, then skyrocketed by 3928.57% to $268000.0 in 2022, then crashed by 77.99% to $59000.0 in 2023, then plummeted by 88.14% to $7000.0 in 2024.
  • Its Asset Writedowns and Impairment stands at $7000.0 for Q4 2024, versus $59000.0 for Q1 2023 and $268000.0 for Q2 2022.